Actually, it's 200k patients. Interestingly with GvHD, if the drug is sufficiently effective, it would expand its own market by allowing transplant procedures that were too risky previously due to prevalence of rejection / GvHD. And if it's effective, it would gain market share here very rapidly since there's not much else in the way of treatments.
Using the previously stated market potential of around $500mm... if it were to gain 40% of market share at its peak and pull in $200mm annually, that would equate to a starting point for valuations of around $600mm using the basic rule of three times peak annual revenue. This would of course be discounted for risk and other considerations, but compare that to our market cap now.
I'd say it moves the needle.
News 
Market Data 
Discover 
